key: cord-0425963-nhg65qjg
authors: Debisarun, P. A.; Gössling, K. L.; Bulut, O.; Kilic, G.; Zoodsma, M.; Liu, Z.; Oldenburg, M.; Rüchel, N.; Zhang, B.; Xu, C.-J.; Struycken, P.; Koeken, V. A. C. M.; Dominguez-Andres, J.; Moorlag, S. J. C. F. M.; Taks, E.; Ostermann, P. N.; Müller, L.; Schaal, H.; Adams, O.; Borkhardt, A.; ten Oever, J.; van Crevel, R.; Li, Y.; Netea, M.
title: Induction of trained immunity by influenza vaccination - impact on COVID-19
date: 2021-09-10
journal: nan
DOI: 10.1101/2021.09.03.21263028
sha: 5cd412e2b245d9681ea448f402f83ab19c896c69
doc_id: 425963
cord_uid: nhg65qjg

Non-specific protective effects of certain vaccines have been reported, and long-term boosting of innate immunity, termed trained immunity, has been proposed as one of the mechanisms mediating these effects. Several epidemiological studies suggested cross-protection between influenza vaccination and COVID-19. In a large academic Dutch hospital, we found that SARS-CoV-2 infection was less common among employees who had received a previous influenza vaccination: relative risk reductions of 37% and 49% were observed following influenza vaccination during the first and second COVID-19 waves, respectively. The quadrivalent inactivated influenza vaccine induced a trained immunity program that boosted innate immune responses against various viral stimuli and fine-tuned the anti-SARS-CoV-2 response, which may result in better protection against COVID-19. Influenza vaccination led to transcriptional reprogramming of monocytes and reduced systemic inflammation. These epidemiological and immunological data argue for potential benefits of influenza vaccination against COVID-19, and future randomized trials are warranted to test this possibility.

Keywords: Influenza vaccine, COVID-19, SARS-CoV-2, trained immunity, cytokines, vaccination 49 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint

As of May 2021, over 150 million cases and 3.1 million deaths due to the novel coronavirus disease 51 COVID-19 have been reported (1). COVID-19 is caused by severe acute respiratory syndrome 52 coronavirus 2 (SARS-CoV-2). While in the majority of cases the virus causes mild symptoms that resolve 53 spontaneously, in the elderly or patients with underlying co-morbidities, the disease is often severe and 54 potentially lethal (2). Due to the rapid spread and high clinical and socio-economic burden of COVID-55 19, sustained efforts have been made to develop preventive and therapeutic strategies (3, 4) . Several 56 effective anti-COVID-19 vaccines have been designed and successfully tested, with almost 1 billion 57 vaccine doses already administered (1). However, vaccine supply is still not able to ensure the global 58 needs, with many countries facing challenges in ensuring access to enough COVID-19 vaccines (5). An 59 additional challenge is the emergence of new SARS-CoV-2 variants which are on the one hand more 60 infective, and on the other hand can display vaccine escape (6). 61

Due to the absence of specific COVID-19 vaccines in the beginning of the pandemic, as well as the 62 current challenges posed by limited vaccine supply and emergence of new virus strains, vaccination 63 strategies using already available vaccines that can protect against a broad array of pathogens has 64 been proposed as 'bridge vaccination' (7). The potential interaction between vaccines and infections 65 other than their target disease has attracted a lot of attention lately. It has been demonstrated that certain 66 vaccines, such as Bacillus Calmette-Guérin (BCG), measles-containing vaccines, or oral polio vaccine, 67 have strong non-specific protective effects through long-term reprogramming of innate immunity, a 68 process called trained immunity (8). In line with this, several recent studies suggested a potential link 69 between influenza vaccination and decreased COVID-19 incidence and severity (9) (10) (11) (12) . This suggests 70 that influenza vaccination may potentially convey partial protection against COVID-19, and this potential 71 beneficial effect needs to be investigated. 72

In this study, we assessed the association between influenza vaccination and COVID-19 incidence 73 during the first two waves of the pandemic in the Netherlands, among employees of the Radboud 74 University Medical Center (Radboudumc), a large academic hospital. In addition, as possible 75 mechanisms of action, we investigated the induction of trained immunity and the impact on systemic 76 inflammation by the influenza vaccine used in the 2020 autumn season in 28 healthy adult volunteers. 77 78 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint 4 2. RESULTS 79

To investigate the effect of influenza vaccination on COVID-19 incidence, we compared the incidence 81 of COVID-19 cases, validated by SARS-CoV-2 PCR, among hospital workers who were either 82 vaccinated or not against influenza. 83

As of June 1 st, 2020, at the end of the first COVID-19 wave in the Netherlands, Radboudumc had 6856 84 employees working in the clinical departments with direct patient contact ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint 5 A lower incidence of SARS-CoV-2 positivity among vaccinated individuals was also reported during the 101 second wave (Table 1), when data for the total number of 10899 Radboudumc employees became  102 available. The hospital's total influenza vaccination coverage rate during the 2020/2021 influenza 103 season was 42% (4529/10899). 91 of the 341 SARS-CoV-2 positive employees (27%) were vaccinated 104 against influenza in the autumn 2020. The COVID-19 incidence during the second wave was 3.92% 105 among unvaccinated employees and 2.00% for vaccinated employees (RR of 0.51, 95% CI 0.40-0.65, 106 P < 0.0001). 107

Our results indicate that influenza vaccination was significantly associated with lower COVID-19 108 incidence among hospital employees during the first two waves of the pandemic. 109 110

To assess a possible induction of trained immunity upon influenza vaccination as the underlying 112 mechanism of protection against SARS-CoV-2, a proof-of-principle study to assess the non-specific 113 immunological effects of the influenza vaccination was performed in 28 healthy individuals. Participants 114 received an influenza vaccine (Influvac Tetra), and blood was collected 1 week before and 6 weeks after 115 vaccination. The study design is summarized in Figure 1 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. immunity. We performed single-cell RNA-sequencing (scRNA-seq) on the peripheral blood mononuclear 125 cells (PBMCs) collected from 10 individuals before and after influenza vaccination. In total, 10,785 cells 126 before and 14,777 cells after vaccination were collected and clustered into 10 subsets, which were 127 annotated by their marker gene expression as CD14+ monocytes, CD16+ monocytes, CD4+ naïve T 128 cells, memory CD4+ T cells, CD8+ T cells, natural killer cells, B cells, dendritic cells and megakaryocytes 129 (S1A Figure) . Immune cell counts were similar after vaccination compared to before (S1B Figure) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint 9 C), proteins related to tumor necrosis factor (TNF) signaling such as TNF receptor-associated factor 4 179 (TRAF4) and TNFRSF14, interleukin 1β (IL-1β), IRAK1, IRAK4, and MAP2K6. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint 12 217

We also quantified the two major cytokines of the IL-1 pathway, IL-1β and IL-1Ra, following the exposure 218 of PBMCs with viral stimuli. SARS-CoV-2-induced IL-1β response was significantly reduced after the 219 influenza vaccination, while poly(I:C) resulted in higher IL-1β production ( Figure 4C ). IL-1β production 220 following SARS-CoV-2 stimulation was below detection limit in 10 individuals before vaccination, and in 221 15 individuals after influenza vaccination. In contrast, SARS-CoV-2 stimulation induced higher IL-1Ra 222 production from PBMCs 6 weeks after the influenza vaccination, compared to the baseline release 223 before vaccination ( Figure 4D ). R848 induced similar concentrations of the innate immune cytokines 224 before and after vaccination. However, a significantly higher IL-12 secretion was observed after poly(I:C) 225 and R848 stimulation ( Figure 4E ). Of note, SARS-CoV-2 and Influenza did not lead to detectable levels 226 of IL-12 in PBMCs. 227 T cell-derived cytokines, IFNγ, IL-17, and IL-22 produced by PBMCs upon heat-killed Influenza 228 stimulation were similar before and after vaccination (S5 Figure) . 229

anti-SARS-CoV-2 responses upon influenza vaccination. Out of 82 inflammatory mediators 231 downregulated by vaccination, 26 were significantly correlated with the production of at least one 232 cytokine ( Figure 5A ). An overwhelming majority of them were positively correlated with the increased 233 ratio in the production of the anti-inflammatory cytokines IL-1Ra and IL-10 after vaccination. Inhibitor of 234 NF-κB kinase regulatory subunit gamma (IKBKG) and TRAF2 were positively correlated with the 235 increase in IL-1β induction, while hepatocyte growth factor (HGF) with IL-6 induction ( Figure 5A is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint

In this study, we present epidemiological and immunological evidence that quadrivalent inactivated 260 influenza vaccination influences the response to and the incidence of SARS-CoV-2 infection. Relative 261 risk reduction for a COVID-19 positive diagnosis in individuals vaccinated against influenza was 37% 262 and 49% during the first and second COVID-19 waves, respectively, suggesting a protective effect of 263 influenza vaccination against infection with SARS-CoV-2. In addition, we found improved 264 responsiveness of immune cells to heterologous viral stimuli after influenza vaccination, arguing for 265 changes in innate immune responses characteristic of a trained immunity program. Moreover, influenza 266 vaccination modulated the responses against SARS-CoV-2, reducing IL-1β and IL-6 production while 267 enhancing IL-1Ra release. 268

Our observation of reduced incidence of COVID-19 in the employees of a Dutch academic hospital is in 269 line with several recent epidemiological studies (S1 Table) . Despite a few reports of a positive 270 association between influenza vaccine coverage and COVID-19 incidence and mortality (13, 14) The healthy vaccinee bias could also play a role in the overestimation of the positive effect of a vaccine: 277 individuals willing to be vaccinated against influenza may be also those more likely to respect the 278 personal protection rules against COVID-19 infection. However, an important argument that influenza 279 vaccination could truly exert protective effects against COVID-19 comes from a Brazilian study showing 280 negative correlations between influenza vaccine and COVID-19 mortality, need of ICU treatment, and 281 invasive respiratory support (18). Correction for comorbidities, several sociodemographic factors, and 282 healthcare facilities uphold the conclusions of this study, and these effects on disease severity in 283 individuals who already contracted COVID-19 cannot be explained by the healthy vaccinee bias. 284

It has been hypothesized that trained immunity might be an important mechanism underlying these 285 beneficial heterologous effects of vaccines (8). The most extensively studied vaccine that induces 286 trained immunity is BCG, which is currently being examined for its putative protective effects against 287 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint 15 COVID-19 duration and severity in several clinical trials (NCT04328441, NCT04348370, NCT04327206, 288 NL8609). Although this property is usually assigned to live vaccines (21), whether inactivated influenza 289 vaccination can also induce trained immunity was not known. Here, we found that Influvac Tetra indeed 290 induces a transcriptional and functional reprogramming of innate immune cells 6 weeks after the 291 vaccination, modulating cytokine responses upon viral challenge with unrelated stimuli. 292

Single-cell RNA sequencing shows that transcriptional programs of both CD14+ monocytes and CD4+ 293 T cells were considerably altered by the seasonal influenza vaccination. Among the most upregulated 294 genes in monocytes, MNDA is an interferon-inducible gene, known to increase in monocytes upon IFNα 295 exposure (22), while Cathepsin S (CTSS) participates in the MHC II-dependent presentation of antigens 296 (23). A similar protein, Cathepsin L, is shown to be critical for SARS-CoV-2 entry through endocytosis 297 (24). By enhancing the uptake, processing, and presentation of SARS-CoV-2 antigens, upregulation of 298 CTSS might be beneficial to induce the anti-viral immune response. Moreover, MNDA is shown to 299 restrict HIV-1 transcription and replication in human macrophages (25), and although not yet explored, 300 similar anti-viral effects may be envisaged against SARS-CoV-2. 301

Three of the most significantly downregulated genes in monocytes, NEAT1, MALAT1 (NEAT2), and 302 SFPQ, contribute to inflammatory responses. Among them, NEAT1 is associated with anti-viral 303 immunity, IL-8, and type I IFN production (26), while MALAT1 induces pro-inflammatory cytokine 304 production (27). In contrast, SFPQ blocks NEAT1 activity by binding to it (26). Similarly, JUN and 305 NFKBIA, which are both downregulated in CD14+ monocytes, oppose each other: JUN is a part of AP-306 1 transcription factor complex stimulating cytokine production (28), while IKBA coded by NFKBIA 307 functions to inhibit NFκB signaling, hence inflammatory response (29). Upregulation of JUN and FOS 308 that form AP-1 together in both CD4+ naïve and memory cells might contribute to improved anti-SARS-309

CoV-2 T cell response. On the other hand, their downregulation in monocytes might be the underlying 310 mechanism of lower IL-6 and IL-1β production observed after stimulation of immune cells of vaccinated 311 individuals with SARS-CoV-2. These data demonstrates that influenza vaccination induces a fine-tuning 312 of the cytokine production to viral stimulation, that could positively influence a balanced inflammatory 313 reaction during infection. 314

Previously, our group showed that the BCG vaccine reduces systemic inflammation, and baseline 315 inflammation is linked with trained immunity (30). In this study, plasma proteomic analyses revealed that 316 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 influenza vaccination also reduced the level of the systemic inflammation status, similarly to BCG. Only 317 GALNT3 was significantly more abundant in the circulation of vaccinated individuals. GALNT3 is known 318 to be upregulated by Influenza A infection, leading to mucin production and affecting virus replication 319 (31). Of note, GALNT3 levels were correlated with lower IL-6 response upon SARS-CoV-2 stimulation 320 after influenza vaccination, possibly contributing to the beneficial effects of the vaccine. On the other 321 hand, 82 proteins related to chemotaxis, apoptosis, and TLR signaling pathways were significantly 322 downregulated by vaccination. Caspases CASP3, CASP8, CASP10, and FAS associated death domain 323 (FADD) are important for apoptosis which is a pathway downregulated upon influenza vaccination (S4 324 Figure) . SARS-CoV-2 was shown to induce cell death via activation of caspase-8, which eventually 325 leads to lung damage (32). Therefore, a lower abundance of the apoptotic proteins in the circulation 326 could contribute to the protection against SARS-CoV-2-related damage. 327

Systemic low-grade inflammation is associated with poor vaccine and immune responses (33). This is 328 in line with the results of this study demonstrating that reduced systemic inflammation induced by 329 influenza vaccination is subsequently associated with a higher pro-inflammatory cytokine production 330 against viral stimuli in vitro, such as Influenza and poly(I:C). In addition, influenza vaccination was 331 followed by a modified pro/anti-inflammatory balance in the IL-1 pathway, with lower IL-1β and IL-6, but 332 higher IL-1Ra response after SARS-CoV-2 stimulation in vitro. Baseline levels of inflammatory 333 modulators were mainly correlated with higher anti-inflammatory cytokine production upon SARS-CoV-334 2 infection in vitro. Fast induction of pro-inflammatory cytokines at the beginning of SARS-CoV-2 335 infection is crucial to decrease the viral load (34). However, anti-inflammatory cytokines, such as IL-336 1Ra, are also necessary to fine-tune the inflammation and counteract excessive inflammation, and it 337 was recently reported to protect against respiratory insufficiency in COVID-19 (35).Together, these 338 cytokines might contribute to keeping a balance in the inflammatory status of the host (36). On the other 339 hand, dysregulation of cytokine responses as during the so-called cytokine storm, is associated with 340 severe disease outcomes (37). Our results indicate that the reprogramming induced by the influenza 341 vaccine could prevent excess inflammation against SARS-CoV-2. We hypothesize that these 342 transcriptomic and proteomic changes induced by influenza vaccination drive immune cells to a distinct 343 functional reprogramming, leading to a balanced response against SARS-CoV-2. 344 A recent study investigated the epigenetic and transcriptional reprogramming as well as cytokine 345 responses of immune cells after a trivalent seasonal influenza vaccine (TIV) and AS03-adjuvanted H5N1 346 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint influenza vaccine (38). Immunization with TIV led to repressive epigenomic state in myeloid cells. 30 347 days after TIV vaccination, PBMCs produced significantly less TNFα, IL-1β, IL-12, IP-10, and IL-1RA 348 upon bacterial and viral challenge, in contrast to our observation of enhanced anti-viral response 6 349 weeks after immunization with a quadrivalent influenza vaccine. Both TIV and the AS03-adjuvanted 350 vaccine reduced the expression of AP-1 transcription factors including FOS and JUN which are highly 351 upregulated in our dataset. On the other hand, the adjuvanted influenza vaccine enhanced the 352 accessibility of anti-viral genes and increased the resistance of PBMCs against Dengue and Zika virus 353

infections. This is another important finding suggesting that heterologous protection can be induced by 354 influenza vaccination. However, it is clear that different types of influenza vaccines, also depending on 355 the adjuvants, induce distinct trained immunity programs. 356

Our study also has important limitations. The hospital population database analysis performed in this 357 study did not allow correction for confounders, as we were not able to access individual characteristics 358 due to hospital privacy policies. A critical possible confounder could be direct patient contact within 359 influenza vaccinated and unvaccinated personnel. However, earlier studies have reported that most 360 SARS-CoV-2 infections in hospital personnel occur in society rather than through patient contact in the 361 hospitals (39-41). Furthermore, there was no information on comorbidities or other exposures outside 362 the hospital environment. While comorbidities are an important factor related to COVID-19 susceptibility 363 and severity, there are no reasons to expect an unequal distribution of comorbidities among influenza 364 vaccinated and unvaccinated personnel for it to cause skewing of the results. Lastly, one cannot rule 365 out healthy-vaccinee bias, which might lead healthier people to better adhere to annual influenza 366 vaccine recommendations. In addition, the in vivo trained immunity effect by influenza vaccination had 367 not been studied as part of a placebo-controlled clinical trial, since healthy volunteers, who had decided 368 autonomously to get vaccinated, were recruited. 369

In conclusion, we provide observational data suggesting a negative association between the 370 quadrivalent inactivated influenza vaccine and COVID-19 incidence. Additionally, we report first insights 371 into the immunological mechanisms underlying these observations. We show that seasonal influenza 372 vaccination can induce a distinct trained immunity program by reducing systemic inflammation and 373 regulating the transcriptional program and cytokine production of circulating immune cells. Considering 374 these data, influenza vaccination may contribute not only to a reduction of influenza but also to the 375 COVID-19-related burden on the healthcare system. Our data show that influenza vaccination is safe in 376 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint

COVID-19 dashboard 2020

Epidemiological and clinical characteristics of 99 504 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

The SARS-CoV-2 Vaccine Pipeline: an Overview

The COVID-19 509 vaccine development landscape

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

Multiple SARS-CoV-2 514 variants escape neutralization by vaccine-induced humoral immunity

Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection

Defining trained 519 immunity and its role in health and disease

Exploratory analysis of immunization records highlights decreased SARS-CoV-521 2 rates in individuals with recent non-COVID-19 vaccinations

Vaccination Coverage Rate and COVID-19 Outbreak: An Italian Ecological Study. Vaccines (Basel)

Impact of the influenza vaccine on 525 COVID-19 infection rates and severity

Inactivated trivalent 527 influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil

Association between Influenza Vaccination Rates and SARS-CoV-2 Outbreak 530 Infection Rates in OECD Countries. SSRN. 2020. 531 14. consortium E. COVID-19 Severity in Europe and the USA: Could the seasonal influenza vaccination play 532 a role? SSRN. 2020. author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted

Epidemiological evidence for association between higher 534 influenza vaccine uptake in the elderly and lower COVID-19 deaths in Italy

Influenza Vaccination 536 and COVID19 Mortality in the USA. medRxiv

Correlation of Influenza Vaccination and Influenza Incidence on COVID-19 Severity and 538 Other Perspectives

Inactivated Trivalent influenza vaccien is associated with lower mortality among 540

Covid-19 patients in Brazil. medRxiv. 2020

Hospitalizations Among COVID-19 Infected Adults

Individualizing Risk Prediction for 544

Testing: Results From 11

Trained innate immunity as underlying mechanism 546 for the long-term, nonspecific effects of vaccines

The human myeloid cell nuclear 548 differentiation antigen gene is one of at least two related interferon-inducible genes located on chromosome 1q 549 that are expressed specifically in hematopoietic cells

Cathepsin S activity regulates 551 antigen presentation and immunity

Characterization of spike glycoprotein of SARS-CoV-2 on 553 virus entry and its immune cross-reactivity with SARS-CoV

Nuclear PYHIN proteins 555 target the host transcription factor Sp1 thereby restricting HIV-1 in human macrophages and CD4+ T cells

Long noncoding RNA 558 NEAT1-dependent SFPQ relocation from promoter region to paraspeckle mediates IL8 expression upon immune 559 stimuli

LncRNA MALAT1 Promotes STAT3-Mediated Endothelial 561 Inflammation by Counteracting the Function of miR-590

The mammalian Jun proteins: redundancy and specificity

NF-kappaB signaling in inflammation

BCG vaccination in humans 567 inhibits systemic inflammation in a sex-dependent manner

Expression of a GalNAc Transferase, GALNT3, via MicroRNAs Is Required for Enhanced Viral Replication

SARS-CoV-2 triggers inflammatory responses and cell 572 death through caspase-8 activation

Targeting Inflammation and Immunosenescence to Improve Vaccine 574 Responses in the Elderly

Association of Early Inflammation with Age

Asymptomatic Disease in COVID-19

Early Anakinra 578 Treatment for COVID-19 Guided by Urokinase Plasminogen Receptor

The role of the interleukin-1 family in trained immunity

How COVID-19 induces 582 cytokine storm with high mortality

The single-cell epigenomic and 584 transcriptional landscape of immunity to influenza vaccination

in Patients Hospitalized at a Large US Academic Medical Center

COVID-19: a retrospective study of 66 hospital-acquired cases in a London teaching hospital

Reducing nosocomial transmission of COVID-19: implementation 591 of a COVID-19 triage system

Souporcell: robust clustering of 593 single-cell RNA-seq data by genotype without reference genotypes

Reference-based analysis of lung single-cell 595 sequencing reveals a transitional profibrotic macrophage

clusterProfiler: an R package for comparing biological themes among 597 gene clusters

relation to a later SARS-CoV-2 infection, and phase III clinical trials to assess its effects on COVID-19 377 are warranted. 378 . CC-BY 4.0 International license It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 10, 2021. The Radboudumc databases on influenza vaccination status and COVID-19 incidence among 382 employees were provided by the Department of Occupational Health and Safety. The hospital databases 383 of SARS-CoV-2 PCR-positive healthcare workers during the first (March -June 2020) and the second 384 (November 2020 -January 2021) COVID-19 waves were consulted, and the corresponding influenza 385 vaccination status of employees was retrieved. Giving the observational nature of this study, ethical 386 waiver was obtained from the Arnhem-Nijmegen Ethical Committee. 387

Hospital database analysis was done using GraphPad Prism 8 (CA, USA). To assess the association 389 between COVID-19 incidence and influenza vaccination status, a Chi-square test was used, and the 390 relative risks (RR) are reported. No correction for confounding was possible because no individual 391 characteristics were available from the databases; only influenza vaccination status and COVID-19 392 history were known. All hospital employees are equally offered an influenza vaccination every year. 393Vaxigrip Tetra and Influvac Tetra were used during the influenza seasons of 2019/2020 and 2020/2021, 394 respectively. It is important to note that SARS-CoV-2 testing at the beginning of the pandemic was only 395 available for employees who were indispensable for patient care due to a shortage of testing materials. 396 397

Subjects and study design 399 28 healthy volunteers, employees of the University Hospital Duesseldorf, were enrolled in the study. 400The average age and BMI were 34.9±8.9 and 22.8±2.8, respectively. 61% of the study participants were 401 female. Participants were vaccinated with 0.5 mL of Influvac Tetra ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint 20 Venous blood was drawn in 3 mL EDTA tubes. The blood was diluted 1:1 with Phosphate Buffered 405 Saline (PBS). Subsequently, PBMCs were isolated using Ficoll-paque (Sigma Aldrich, Taufkirchen, 406 Germany) density gradient centrifugation. The PBMCs layer was collected and washed twice in cold 407 PBS. Cells were reconstituted in RPMI+, consisting of RPMI-1640 culture medium (Sigma Aldrich, 408Taufkirchen, Germany) supplemented with 10 µg/mL gentamicin, 10 mM L-glutamine and 10 mM 409 pyruvate (Gibco). 410Stimulations were performed in the presence of 2% human AB serum (Sigma Aldrich, Taufkirchen, 411Germany) for the 24h-stimulations and 10% human serum for the 7-day-stimulations. Cells were 412 incubated at 37°C with 5% CO2, after 24 hours or 7 days, respectively, supernatants were collected and 413 stored at -80°C. 414End-concentration of the stimuli: pathogens and recombinant PAMPs 415Heat-inactivated Influenza B Brisbane (7,4*10x3 K/mL TCID50), heat-inactivated Influenza H1N1 416 California (3,24 x 10x5 K/mL TCID50), and heat-inactivated SARS-CoV-2 Wuhan-Hu-1 variant (1,4 x 417 10x3K/mL TCID50) were used in the study. Viruses had been heat-inactivated for 30 minutes at 60 o C. 418Heat-inactivation had been checked for sufficiency by cell culture inoculation and subsequent qPCR 419 testing. R848 (Resiquimod, TLR7/8 ligand) (Invivogen, San Diego, CA, USA) (3 μg/mL); Poly I:C (TLR3 420 ligand) (Invivogen, San Diego, CA, USA) (10 μg/mL). 421Cytokine measurements 422 IL-1β, IL-1Ra, IL-10, IFNα, and IL-12p70 were measured in the cell culture supernatants after 24h 423 stimulation using a custom-made multiplex ELISA kit (Procartaplex, Life Technologies GmbH, 424Darmstadt, Germany) according to the instructions supplied by the manufacturer. IL-6 and TNFα were 425 measured after 24h stimulation and IL-17, IFNγ and IL-22 were measured after 7 days stimulation in the 426 cell culture supernatant using a duo-set ELISA according to the protocol supplied by the manufacturer 427 (R&D systems, Minneapolis. MN, USA). Differences between cytokine productions before and after 428 influenza vaccination were analyzed using the Wilcoxon signed-rank test. All calculations were 429 performed in GraphPad Prism 8. A p-value lower than 0.05 was considered statistically significant. 430Proteomics measurements and analysis 431 . CC-BY 4.0 International license It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 10, 2021. After demultiplexing, we used the R package Seurat (v4.0.1) for downstream analysis. For quality 456 control, we excluded cells that met the one of the following criteria: mitochondrial content > 25%, either 457 < 100 or > 3000 detected genes per cell, and > 5000 detected transcripts per cell. Furthermore, 458 mitochondrial genes and ribosomal genes were removed from further analyses. Then, gene expression 459 . CC-BY 4.0 International license It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint 22 values were normalized by total UMI counts per cell, multiplied by 10,000 (TP10k) and log-transformed 460 by log10 (TP10k+1) . 461Subsequently, we followed a typical Seurat clustering workflow with the following steps: First, we 462 selected the 2,000 most variable features and scaled against the number of UMIs. PCA was performed, 463 followed by Shared Nearest Neighbor (SNN) Graph construction using PC1 through PC20 to identify 464 cell clusters. Finally, Uniform Manifold Approximation and Projection (UMAP) was used to visualize the 465 cell clusters. Cell type annotation was based on the following canonical gene markers and combined 466 with SingleR (43) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 10, 2021. ; https://doi.org/10.1101/2021.09.03.21263028 doi: medRxiv preprint